Sermorelin is a synthetic peptide consisting of the first 29 amino acids of GHRH (growth hormone releasing hormone) — the minimum sequence needed to stimulate GH release. It was FDA-approved for diagnosing GH deficiency in children and for treating GH deficiency in HIV-related wasting, though both approvals were subsequently withdrawn from the market by the manufacturer for commercial rather than safety reasons.
Growth Hormone Deficiency Research
Sermorelin has been studied extensively for GH deficiency in children and adults. It stimulates the pituitary to produce natural GH rather than replacing it with exogenous HGH. Studies show it can raise GH and IGF-1 levels meaningfully in deficient individuals.
Adult Body Composition
Research has examined sermorelin in adults with age-related GH decline. Studies show it can restore GH pulse amplitude and IGF-1 levels in older adults and is associated with improvements in body composition, sleep quality, and energy in some studies.
HIV-Associated Wasting
Sermorelin was studied and approved for HIV-associated wasting (lipodystrophy), with research showing improvements in lean mass and fat distribution in this population.
Stimulates pituitary GH release — works through the body's natural regulatory system rather than bypassing it.
Raises IGF-1 and GH levels in both GH-deficient and age-declined populations.
Studies show body composition improvements in adults with GH decline.
Previously FDA-approved (withdrawn from market for commercial reasons, not safety).
Has a ceiling effect — the pituitary's own regulatory mechanisms still apply.
Sermorelin was withdrawn from the US market by its manufacturer (not due to safety concerns but commercial reasons), so it is no longer available as an FDA-approved product. The half-life of the peptide is short (about 12 minutes), requiring daily or twice-daily injections for sustained effect. Long-term data beyond study periods are limited. Like all GH-stimulating compounds, considerations around insulin-like growth factor elevation and its long-term implications apply.
GHRH is the natural signal from the hypothalamus that tells the pituitary gland to release growth hormone. Sermorelin is a shorter version of GHRH that retains full biological activity — the first 29 amino acids are sufficient to activate the GHRH receptor on pituitary cells. When injected, sermorelin travels to the pituitary and triggers a burst of GH release, similar to what happens naturally during sleep or exercise. Unlike exogenous HGH, which delivers ready-made growth hormone and suppresses the body's own GH production, sermorelin works through the body's existing regulatory pathway. The pituitary still controls the response, which acts as a natural check on how much GH is released.
Sermorelin has a well-characterized safety profile from its FDA-approved clinical history. Side effects include injection site reactions, flushing, and headache. Because it stimulates natural GH production with the pituitary's regulatory mechanisms intact, the risk of GH excess is lower than with exogenous HGH. It is no longer commercially available as an FDA-approved product but is compounded by licensed compounding pharmacies. Use outside of a medical context is not appropriate.
High Evidence
This compound has been studied in multiple large randomized controlled trials with human subjects. The evidence base is strong and consistent across independent research groups.
Published Research Ranges
0.2–0.3mg/kg at bedtime in clinical studies; 0.5–2mg/day studied
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Sermorelin Acetate in Growth Hormone Deficiency: Efficacy and Safety
The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients with longstanding post-irradiation GH insufficiency
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.